Approvals & Mergers: Inside Enzyvant with Bill Symonds, Pharm.D.
Business Of Biotech
00:00
The Struggles of Altavant and Rethomica
There are very different patient populations between the two companies. Altavant is going after a theory or concept called that the serotonin hypothesis, which has been around for 25 plus years. And then we finally in rhodatrist, I have a drug which is systemically available, which can reduce the systemic levels of serotonin - not affecting the ones in the brain.
Transcript
Play full episode
